Incannex Healthcare
Market cap $21.8M 12.5M shares (10-Q, Nov 9, 2026) × $1.74 close Nov 17, 2026
Most recent annual filing: 2026-09-25
- DReAMzz corporate updatemid-2027DReAMzz corporate update, mid-2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
psilocybin
PSX-001Discontinued (1)
- IHL-675A — Rheumatoid Arthritis · Phase 2 trial terminated due to challenges with patient recruitment; insufficient data collected
Capital (as filed)
- Cash
- $68.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- $521K quarter to Sep 30, 2026 (10-Q)
- As stated in coverage
- $68.3M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-13 UPDATE: Incannex (IXHL) - The Topline Date Lands, and the Stock Trades at 37 Cents on the Cash Dollar 🔒 Paid
- 2026-08-25 UPDATE: Incannex (IXHL) - First Patient Dosed. The Checkpoint I Named Just Cleared. 🔒 Paid
- 2026-06-25 UPDATE: Incannex (IXHL) - One of the Four BUY Triggers Just Fired. The Other Three Didn’t.
- 2026-05-15 UPDATE: Incannex (IXHL) - DReAMzz Officially Starts. The Clock on Dead Money Begins. 🔒 Paid
- 2026-04-27 UPDATE: Incannex (IXHL) - The White House Throws Psychedelics a Bone, and IXHL Grabs the Microphone
- 2026-03-28 UPDATE: Incannex (IXHL) - Buying Goodwill and Baffling Buybacks
- 2026-03-21 UPDATE: Incannex (IXHL) - Damage Control, Negative Enterprise Value, and the Reality of Biotech Markets
- 2026-03-14 UPDATE: Incannex (IXHL) - The Goalposts Move, The Dilution Hits, and Phase 3 is Delayed to 2027
- 2026-02-28 UPDATE: Incannex (IXHL) - The Predicted Reverse Split Arrives...
- 2026-02-14 UPDATE: Incannex (IXHL) - Q2 Fiscal 2026 Update
- 2026-01-11 Incannex (IXHL): Scientific Deep Dive for IHL-42X and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Incannex Healthcare, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-11 Watch Incannex (IXHL): Scientific Deep Dive for IHL-42X and Pipeline Products Incannex has plausible science and adequate cash but faces competitive pressure from Apnimed and GLP-1s; wait for FDA Phase 3 design clarity before committing capital.
- 2026-02-14 Watch UPDATE: Incannex (IXHL) - Q2 Fiscal 2026 Update Nothing in the 10-Q changes the core thesis; Incannex is well-funded but the valuation rests entirely on the H1 2026 FDA meeting for IHL-42X.
- 2026-02-28 Watch UPDATE: Incannex (IXHL) - The Predicted Reverse Split Arrives... The 1-for-30 reverse split is mechanical Nasdaq compliance engineering; the entire thesis still rests on the H1 2026 FDA meeting for IHL-42X, so stay on the sidelines.
- 2026-03-14 Avoid UPDATE: Incannex (IXHL) - The Goalposts Move, The Dilution Hits, and Phase 3 is Delayed to 2027 Phase 3 delayed to 2H 2027, a dilutive $10M RDO with 100% warrant coverage was issued despite $69M in cash, and the near-term binary catalyst is gone — thesis is broken.
- 2026-03-21 Avoid UPDATE: Incannex (IXHL) - Damage Control, Negative Enterprise Value, and the Reality of Biotech Markets Management's negative-enterprise-value complaint ignores that the market is pricing in the 18-month Phase 3 delay, dilution overhang, and confusing capital allocation; avoid the value trap.
- 2026-03-28 Avoid UPDATE: Incannex (IXHL) - Buying Goodwill and Baffling Buybacks Management is financially engineering a price floor via buybacks while simultaneously having diluted the float with warrants — true value requires clinical data, not stock arbitrage.
- 2026-04-27 Avoid UPDATE: Incannex (IXHL) - The White House Throws Psychedelics a Bone, and IXHL Grabs the Microphone The White House EO is a class tailwind for psilocybin but not an Incannex-specific catalyst; the broken IHL-42X timeline, toxic capital structure, and second-tier psychedelic positioning are unchanged.
- 2026-05-15 Avoid UPDATE: Incannex (IXHL) - DReAMzz Officially Starts. The Clock on Dead Money Begins. DReAMzz commencing is a necessary milestone but not a sufficient one; the 2H 2027 Phase 3 wall, warrant overhang, and dilution bazooka are all unchanged.
- 2026-06-25 Avoid UPDATE: Incannex (IXHL) - One of the Four BUY Triggers Just Fired. The Other Three Didn't. A US composition patent on IHL-42X is a real IP de-risking but only one of the four required BUY triggers; the 18-month dead-money window, warrant overhang, and missing partnership/FDA green light keep the thesis broken.
- 2026-08-25 Avoid UPDATE: Incannex (IXHL) - First Patient Dosed. The Checkpoint I Named Just Cleared. First patient dosed in DReAMzz is real operational progress but not one of the four BUY triggers; Phase 3 still gated to 2H 2027 and capital structure problems remain unresolved.
- 2026-11-13 Avoid UPDATE: Incannex (IXHL) - The Topline Date Lands, and the Stock Trades at 37 Cents on the Cash Dollar Mid-2027 DReAMzz completion date confirms the dead-money window rather than shortening it; PSX-001 stalled at redesign, buyback unused during 46% decline, and no catalyst exists before mid-2027.
- Avoid call · opened Mar 16, 2026 at $3.31 · -47.4% vs XBI +17.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (33)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 202610-QQuarterly report→ BD updateIncannex's Q1 FY2027 10-Q reveals the cash burn has essentially vanished — net operating cash flow turned positive at +$0.5M vs. the -$9.2M quarter a year ago — extending the runway dramatically even as DReAMzz narrows its completion estimate to mid-2027.
- Oct 28, 2026DEFA14AProxy soliciting material
- Oct 28, 2026DEF 14AProxy statement
- Oct 1, 2026ReleaseStonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26BD extracted 1 program update from this document → IXHL pipeline
- Sep 25, 202610-KAnnual reportBD extracted 1 program update from this document → IXHL pipeline
- Sep 9, 2026ReleaseIncannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
- Sep 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF SEPTEMBER 9, 2026BD extracted 2 program updates from this document → IXHL pipeline
- Aug 25, 2026ReleaseIncannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X→ BD updateSummary on the 8-K
- Aug 25, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF AUGUST 25, 2026→ BD updateThe first patient has been dosed in DReAMzz — the exact checkpoint I flagged as the next editorial moment. The milestone is real; the 2H 2027 Phase 3 wall, the $6.50 warrant overhang, and the capital-structure mess are still standing.
- Aug 11, 2026ReleaseIncannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
- Aug 11, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF AUGUST 11, 2026
- Jul 23, 2026ReleaseIncannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
- Jul 23, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JULY 23, 2026
- Jun 25, 2026ReleaseIncannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
- Jun 25, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JUNE 25, 2026
- Jun 10, 2026ReleaseIncannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
- Jun 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JUNE 10, 2026
- Jun 9, 2026ReleaseIncannex Announces Initiation of Research Coverage by Alliance Global Partners
- Jun 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF JUNE 9, 2026
- May 15, 202610-QQuarterly report
- May 14, 2026ReleaseIncannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
- May 14, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MAY 14, 2026
- May 12, 2026ReleaseIncannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
- May 12, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MAY 12, 2026
- Apr 22, 2026ReleaseIncannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
- Apr 22, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF APRIL 22, 2026
- Mar 27, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MARCH 27, 2026
- Mar 25, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MARCH 25, 2026
- Mar 18, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MARCH 18, 2026
- Mar 17, 20268-KCurrent report: listing notice, other events · EX-99.1 PRESS RELEASE ISSUED BY INCANNEX HEALTHCARE INC., DATED MARCH 17, 2026
- Mar 12, 20268-KCurrent report: material agreement, other events · EX-99.1 PRICING PRESS RELEASE, DATED MARCH 12, 2026
- Mar 12, 20268-KCurrent report: agreement terminated, Reg FD disclosure, other events · EX-99.1 CORPORATE PRESENTATION, DATED MARCH 12, 2026
- Mar 12, 2026424B5Prospectus supplement (offering)
2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 28, 2026ARSAnnual report to shareholders
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)